Europe

Magazine articles on conducting business in European countries.

Old Articles: <Older 1751-1760 Newer>

The Motley Fool May 1, 2007 Tom Taulli	ISE's Shares Scorching Hot The German exchange Deutsche Boerse makes a bold play for the U.S. options market. Shares are already approaching the $67.50 buyout price, raising speculation that other bidders will come to the table.
The Motley Fool May 1, 2007 S.J. Caplan	Amvescap Ambles On The U.K.-based asset management firm reports quarterly earnings. Investors, take note.
The Motley Fool May 1, 2007 Seth Jayson	Quick Take: U.K. Nuttier Than U.S. Lowering loan underwriting standards and raising the amount you'll give out: It's worked out pretty horribly here. But hey, things must be different in the U.K., right?
The Motley Fool April 30, 2007 Brian Lawler	Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris.
BusinessWeek May 7, 2007 Kerry Capell	The Trouble With London's Traffic Tolls Since London imposed an ambitious congestion-pricing scheme in 2003, it has raised the fee to drive into the most heavily congested parts of town by 60%.
BusinessWeek May 7, 2007 Stanley Reed	Europe: The Making Of A Monolith ABN AMRO signals the euro zone's superpower status.
BusinessWeek May 7, 2007 Jack Ewing	A Setback For German Reform Ousted Siemens CEO Klaus Kleinfeld was emblematic of a nation's turnaround.
The Motley Fool April 25, 2007 Rich Duprey	Escala's Ephemeral Value Targeted by Spanish authorities, the coin-and-stamp trading firm inches closer to liquidation. Today, the stock sits at $4 a share, just about where it traded immediately after the scandal broke, despite the greater clarity available to investors.
The Motley Fool April 25, 2007 Toby Shute	BP Books Passable Profits The oil and gas giant from across the pond turned in another lackluster quarter. Investors, take note.
Chemistry World April 24, 2007 Victoria Gill	AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune.
<Older 1751-1760 Newer> Return to current articles.